Trexquant Investment LP Has $1.38 Million Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Trexquant Investment LP raised its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 267.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,966 shares of the company's stock after acquiring an additional 130,960 shares during the period. Trexquant Investment LP owned approximately 0.49% of iTeos Therapeutics worth $1,382,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after purchasing an additional 1,601,477 shares in the last quarter. State Street Corp increased its stake in shares of iTeos Therapeutics by 21.9% during the third quarter. State Street Corp now owns 1,175,353 shares of the company's stock valued at $12,000,000 after acquiring an additional 211,452 shares during the period. Raymond James Financial Inc. bought a new stake in iTeos Therapeutics during the fourth quarter worth approximately $1,159,000. Peapod Lane Capital LLC acquired a new stake in iTeos Therapeutics in the fourth quarter worth approximately $836,000. Finally, KLP Kapitalforvaltning AS bought a new position in iTeos Therapeutics during the 4th quarter valued at $299,000. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS traded up $0.41 during mid-day trading on Tuesday, hitting $5.94. The stock had a trading volume of 137,583 shares, compared to its average volume of 462,984. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.75. The company has a market cap of $226.72 million, a PE ratio of -1.89 and a beta of 1.43. The company's 50 day moving average is $6.70 and its 200-day moving average is $7.78.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13. On average, equities research analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ITOS shares. Wells Fargo & Company cut their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Wedbush reaffirmed an "outperform" rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright reissued a "buy" rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.